Physician profile
Christian G Samuelson
NPI 1457795676
$14,705.45
in general payments reported to CMS, 2019-2025
29 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,610 · 2020: $1,214 · 2021: $5,122 · 2022: $2,413 · 2023: $2,306 · 2024: $835 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616 · Travel and Lodging: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.89 |
| Travel and Lodging | $731.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $5,176.35 | 2019-2024 | Senza |
| Medtronic, INC. | $3,810.37 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $1,874.01 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $880.27 | 2025 | Senza, Vyrsa V1 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $639.64 | 2019-2025 | Relistor |
| Abbott Laboratories | $454.61 | 2019-2021 | |
| Saluda Medical Americas, INC. | $341.82 | 2023-2025 | Evoke Scs, Evoke |
| Pacira Therapeutics, INC. | $219.23 | 2019 | |
| Si-Bone, INC. | $214.14 | 2019-2024 | |
| Medtronic USA, INC. | $167.14 | 2020 | |
| Assertio Therapeutics, INC. | $165.33 | 2019-2020 | |
| Dova Pharmaceuticals | $122.62 | 2019 | |
| Mdd US Operations, LLC | $81.06 | 2020 | |
| Arbor Pharmaceuticals, INC. | $64.77 | 2021-2022 | |
| Fidia Pharma USA INC. | $56.91 | 2021-2025 | Triluron, Hymovis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $50.90 | 2020-2021 | |
| Almatica Pharma LLC | $49.48 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $39.68 | 2023-2024 | Horizant, Horizant |
| Pfizer INC. | $39.36 | 2020-2021 | |
| Abbvie INC. | $38.40 | 2021-2024 | |
| Grt US Holding, INC. | $37.23 | 2021-2022 | |
| Valinor Pharma, LLC | $36.44 | 2025 | Movantik |
| Biodelivery Sciences International, INC. | $29.82 | 2021 | |
| Spr Therapeutics, INC | $29.35 | 2023 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $26.60 | 2019 | |
| Relievant Medsystems, INC. | $19.75 | 2023 | Intracept |
| Bioventus LLC | $14.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.21 | 2019 | |
| Daiichi Sankyo INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Samuelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.